Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$59.24 USD
-0.26 (-0.44%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $59.26 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HALO 59.24 -0.26(-0.44%)
Will HALO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Other News for HALO
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
Interesting HALO Put And Call Options For November 15th
Halozyme cut to Neutral at J.P. Morgan on valuation
Five Below downgraded, DoorDash upgraded: Wall Street's top analyst calls
Halozyme just downgraded at JPMorgan, here's why